154 related articles for article (PubMed ID: 28931365)
21. Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy.
Trucco E; Tolosana JM; Castel MÁ; Batlle M; Borràs R; Sitges M; Guash E; Matas M; Arbelo E; Berruezo A; Brugada J; Mont L
Europace; 2016 Feb; 18(2):232-7. PubMed ID: 25883077
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
23. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
24. Correlation of Baseline Plasma and Inguinal Connective Tissue Metalloproteinases and Their Inhibitors With Late High-Pressure Endoleak After Endovascular Aneurysm Repair: Long-term Results.
Georgiadis GS; Antoniou GA; Argyriou C; Schoretsanitis N; Nikolopoulos E; Kapoulas K; Lazarides MK; Tentes I
J Endovasc Ther; 2019 Dec; 26(6):826-835. PubMed ID: 31464166
[No Abstract] [Full Text] [Related]
25. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
26. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
Hoffmann U; Brueckmann M; Borggrefe M
Crit Care; 2009; 13(6):1006. PubMed ID: 20017890
[TBL] [Abstract][Full Text] [Related]
28. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
[TBL] [Abstract][Full Text] [Related]
29. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
30. [Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation.].
Kim LB; Russkih GS; Putyatina AN; Tsypysheva OB
Adv Gerontol; 2018; 31(2):223-230. PubMed ID: 30080329
[TBL] [Abstract][Full Text] [Related]
31. Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis-associated coagulopathy.
Sivula M; Hästbacka J; Kuitunen A; Lassila R; Tervahartiala T; Sorsa T; Pettilä V
Acta Anaesthesiol Scand; 2015 Feb; 59(2):176-84. PubMed ID: 25329743
[TBL] [Abstract][Full Text] [Related]
32. Targeting matrix metalloproteinases with intravenous doxycycline in severe sepsis--A randomised placebo-controlled pilot trial.
Nukarinen E; Tervahartiala T; Valkonen M; Hynninen M; Kolho E; Pettilä V; Sorsa T; Backman J; Hästbacka J
Pharmacol Res; 2015 Sep; 99():44-51. PubMed ID: 26008138
[TBL] [Abstract][Full Text] [Related]
33. The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.
Marc A; Pop C; Sitar-Taut AV; Budisan L; Berindan-Neagoe I; Pop D
BMC Cardiovasc Disord; 2021 Dec; 21(1):607. PubMed ID: 34930125
[TBL] [Abstract][Full Text] [Related]
34. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
[TBL] [Abstract][Full Text] [Related]
36. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
38. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.
Lorente L; Martín M; Plasencia F; Solé-Violán J; Blanquer J; Labarta L; Díaz C; Borreguero-León JM; Jiménez A; Páramo JA; Orbe J; Rodríguez JA; Salido E
Crit Care; 2013 May; 17(3):R94. PubMed ID: 23706069
[TBL] [Abstract][Full Text] [Related]
39. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
[TBL] [Abstract][Full Text] [Related]
40. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
